{
    "organizations": [],
    "uuid": "ef966a6fcda813c3bd2c35c2b70535b322b83845",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-regeneron-says-phase-3-trial-of-du/brief-regeneron-says-phase-3-trial-of-dupixent-met-primary-endpoints-idUSASC0A2JF",
    "ord_in_thread": 0,
    "title": "BRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary Endpoints",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Regeneron Pharmaceuticals Inc:\n* POSITIVE PHASE 3 TRIAL OF DUPIXENTÂ® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS\n* U.S. REGULATORY SUBMISSION FOR PATIENTS AGES 12-17 PLANNED FOR Q3 2018\n* CO, SANOFI SAID PIVOTAL PHASE 3 TRIAL EVALUATING DUPIXENT MET PRIMARY AND KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-16T13:05:00.000+03:00",
    "crawled": "2018-05-17T14:41:07.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "positive",
        "phase",
        "trial",
        "dupilumab",
        "adolescent",
        "inadequately",
        "controlled",
        "atopic",
        "dermatitis",
        "regulatory",
        "submission",
        "patient",
        "age",
        "planned",
        "q3",
        "co",
        "sanofi",
        "said",
        "pivotal",
        "phase",
        "trial",
        "evaluating",
        "dupixent",
        "met",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}